Skip to content

Study · Other design · 2024

8 results

Amylin receptor agonism enhances the effects of liraglutide in protecting against the acute metabolic side effects of olanzapine.

Medak KD, Jeromson S, Bellucci A, Arbeau M, Wright DC

iScience4 Dec 2023Cited by 2 (Europe PMC)

PMID38188526 (opens in a new tab)PMCIDPMC10767228 (opens in a new tab)DOI10.1016/j.isci.2023.108628 (opens in a new tab)PepBankPUB-38188526
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

Olanzapine is a second-generation antipsychotic (AP) used in the management of schizophrenia. Although effective at reducing psychoses, APs cause rapid hyperglycemia, insulin resistance, and dyslipidemia, an effect mediated in part by glucagon. We tested if amylin, a hormone that reduces glucagon, or the amylin receptor agonist pramlintide would protect against acute olanzapine-induced impairments in glucose and lipid homeostasis alone or in combination with other glucose-lowering agents such as liraglutide. We demonstrated that pramlintide lowered olanzapine-induced increases in glucagon:insulin ratio with a trend to protect against excursions in blood glucose. There was an additive effect of pramlintide and liraglutide in protecting against olanzapine-induced hyperglycemia, which was mirrored by reductions in glucagon and attenuated markers of dyslipidemia. Our findings provide evidence that pramlintide, although moderately protective against some aspects of olanzapine-induced metabolic dysfunction, can be used to enhance the protective effects of other interventions against acute olanzapine-induced metabolic dysfunction.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabOther designEfficacy outcome

    In an unspecified experimental model, pramlintide reduced the olanzapine-induced increase in glucagon:insulin ratio.

    In plain wordsIn lab tests with an unspecified model, pramlintide reduced the hormone ratio increase caused by olanzapine.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseGlucagon:insulin ratio
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We demonstrated that pramlintide lowered olanzapine-induced increases in glucagon:insulin ratio with a trend to protect against excursions in blood glucose.
  2. 02LabOther designEfficacy outcome

    In an unspecified experimental model, pramlintide showed a trend toward protection against olanzapine-induced blood glucose excursions.

    In plain wordsIn lab tests with an unspecified model, pramlintide showed a trend toward limiting blood sugar increases caused by olanzapine.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseBlood glucose excursions
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We demonstrated that pramlintide lowered olanzapine-induced increases in glucagon:insulin ratio with a trend to protect against excursions in blood glucose.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 03LabNot a test of Pramlintide (Symlin) aloneOther designEfficacy outcome

    In an unspecified model, pramlintide and liraglutide showed additive protection against olanzapine-induced hyperglycemia.

    In plain wordsIn lab tests with an unspecified model, pramlintide and liraglutide together showed additive protection against high blood sugar caused by olanzapine.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseHyperglycemia with combination
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    There was an additive effect of pramlintide and liraglutide in protecting against olanzapine-induced hyperglycemia, which was mirrored by reductions in glucagon and attenuated markers of dyslipidemia.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  2. 04LabNot a test of Liraglutide aloneOther designEfficacy outcome

    In an unspecified model, pramlintide and liraglutide showed additive protection against olanzapine-induced hyperglycemia.

    In plain wordsIn lab tests with an unspecified model, pramlintide and liraglutide together showed additive protection against high blood sugar caused by olanzapine.

    Peptide
    Liraglutide
    Outcome
    DecreaseHyperglycemia with combination
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    There was an additive effect of pramlintide and liraglutide in protecting against olanzapine-induced hyperglycemia, which was mirrored by reductions in glucagon and attenuated markers of dyslipidemia.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 05LabNot a test of Pramlintide (Symlin) aloneOther designEfficacy outcome

    In an unspecified model, pramlintide plus liraglutide reduced glucagon during protection against olanzapine-induced metabolic effects.

    In plain wordsIn lab tests with an unspecified model, the pramlintide and liraglutide combination reduced glucagon.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseGlucagon with combination
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    There was an additive effect of pramlintide and liraglutide in protecting against olanzapine-induced hyperglycemia, which was mirrored by reductions in glucagon and attenuated markers of dyslipidemia.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  4. 06LabNot a test of Liraglutide aloneOther designEfficacy outcome

    In an unspecified model, pramlintide plus liraglutide reduced glucagon during protection against olanzapine-induced metabolic effects.

    In plain wordsIn lab tests with an unspecified model, the pramlintide and liraglutide combination reduced glucagon.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlucagon with combination
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    There was an additive effect of pramlintide and liraglutide in protecting against olanzapine-induced hyperglycemia, which was mirrored by reductions in glucagon and attenuated markers of dyslipidemia.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 07LabNot a test of Pramlintide (Symlin) aloneOther designEfficacy outcome

    In an unspecified model, pramlintide plus liraglutide attenuated markers of olanzapine-induced dyslipidemia.

    In plain wordsIn lab tests with an unspecified model, the pramlintide and liraglutide combination reduced markers of abnormal blood fats caused by olanzapine.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseDyslipidemia markers with combination
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    There was an additive effect of pramlintide and liraglutide in protecting against olanzapine-induced hyperglycemia, which was mirrored by reductions in glucagon and attenuated markers of dyslipidemia.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  6. 08LabNot a test of Liraglutide aloneOther designEfficacy outcome

    In an unspecified model, pramlintide plus liraglutide attenuated markers of olanzapine-induced dyslipidemia.

    In plain wordsIn lab tests with an unspecified model, the pramlintide and liraglutide combination reduced markers of abnormal blood fats caused by olanzapine.

    Peptide
    Liraglutide
    Outcome
    DecreaseDyslipidemia markers with combination
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    There was an additive effect of pramlintide and liraglutide in protecting against olanzapine-induced hyperglycemia, which was mirrored by reductions in glucagon and attenuated markers of dyslipidemia.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.